Structure Therapeutics (GPCR) Competitors

Structure Therapeutics (NASDAQ:GPCR) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Which has more volatility and risk, GPCR or ACAD?

Structure Therapeutics has a beta of -1.89, suggesting that its share price is 289% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Does the media prefer GPCR or ACAD?

In the previous week, ACADIA Pharmaceuticals had 5 more articles in the media than Structure Therapeutics. MarketBeat recorded 37 mentions for ACADIA Pharmaceuticals and 32 mentions for Structure Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.70 beat Structure Therapeutics' score of -0.32 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	2 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	7 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings and valuation, GPCR or ACAD?

ACADIA Pharmaceuticals has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$122.53M	-$1.05	-17.85
ACADIA Pharmaceuticals	$957.80M	4.48	$226.45M	$1.33	19.14

Do analysts recommend GPCR or ACAD?

Structure Therapeutics presently has a consensus target price of $75.71, suggesting a potential upside of 304.03%. ACADIA Pharmaceuticals has a consensus target price of $28.88, suggesting a potential upside of 13.46%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Structure Therapeutics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
ACADIA Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61

Do insiders and institutionals believe in GPCR or ACAD?

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 5.6% of Structure Therapeutics shares are held by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Is GPCR or ACAD more profitable?

ACADIA Pharmaceuticals has a net margin of 21.80% compared to Structure Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 14.69% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-21.31%	-20.34%
ACADIA Pharmaceuticals	21.80%	14.69%	9.41%

Summary

ACADIA Pharmaceuticals beats Structure Therapeutics on 14 of the 16 factors compared between the two stocks.